A multiple drug interaction study of stavudine with agents for opportunistic infections in human immunodeficiency virus-infected patients

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 3, 1999, Pages 647-650

  Piscitelli, Stephen C ^a   Kelly, Grace ^a   Walker, Robert E ^a   Kovacs, Joseph ^a   Falloon, Judith ^a   Davey Jr , Richard T ^a   Raje, Sangita ^a   Masur, Henry ^b   Polis, Michael A ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CLARITHROMYCIN; COTRIMOXAZOLE; FLUCONAZOLE; PENTAMIDINE; RIFABUTIN; STAVUDINE; VIRUS DNA;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; OPPORTUNISTIC INFECTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0033055842     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.3.647     Document Type: Article

References (22)

1. Cretton, E. M., Z. Zhou, L. B. Kidd, H. M. McClure, S. Kaul, M. J. M. Hitchcock, and J.-P. Sammadossi. 1993. In vitro and in vivo disposition and metabolism of 3′-deoxy-2′,3′-dideoxyhydrothymidine. Antimicrob. Agents Chemother. 37:1816-1825.
2. Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health. 1995. Protocol management handbook. National Institutes of Health, Bethesda, Md.
3. Fletcher, C. V. Personal communication.
4. Hammer, S. M., K. E. Squires, M. D. Hughes, J. M. Grimes, L. M. Demeter, J. S. Currier, J. J. Eron, J. E. Feinberg, H. H. Balfour, Jr., L. R. Deyton, J. A. Chodakewitz, and M. A. Fischl. 1997. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N. Engl. J. Med. 337:725-733.
5. Hoggard, P. G., S. Kewn, M. G. Barry, S. H. Khoo, and D. J. Back. 1997. Effects of drugs on 2′,3′-dideoxy-2′,3′-didehydrothymidine phosphorylation in vitro. Antimicroh. Agents Chemother. 41:1231-1236.
6. Lew, E. A., M. A. Poles, and D. T. Dietrich. 1997. Diarrheal diseases associated with HIV infection. Gastroenterol. Clin. N. Am. 26:259-290.
7. Monpoux, F., N. Sirvent, J. Cottalorda, R. Mariani, and J. C. Lefebvre. 1997. Stavudine, lamivudine and indinavir in children with advanced HIV-1 infection: preliminary experience. AIDS 11:1523-1525.
8. National Institute of Allergy and Infectious Diseases. 22 November 1996. Important therapeutic information on the combination of zidovudine and stavudine in patients who have previously taken zidovudine. (Press release.)
9. Peloquin, C. A., A. T. Nitta, W. J. Burman, K. F. Brudney, J. R. Miranda-Massari, M. E. McGuinness, S. E. Berning, and G. T. Gerena. 1996. Low antituberculosis drug concentrations in patients with AIDS. Antimicrob. Agents Chemother. 30:919-925.
10. Piscitelli, S. C., C. Flexner, J. R. Minor, M. A. Polis, and H. Masur. 1996. Drug interactions in patients infected with human immunodeficiency virus. Clin. Infect. Dis. 23:685-693.
11. Polis, M. A., S. C. Piscitelli, S. Vogel, F. G. Witebsky, P. S. Conville, B. Petty, J. A. Kovacs, R. T. Davey, Jr., R. E. Walker, J. Falloon, J. A. Metcalf, C. Craft, H. C. Lane, and H. Masur. 1997. Clarithromycin lowers plasma zidovudine levels in persons with human immunodeficiency virus infection. Antimicrob. Agents Chemother. 41:1709-1714.
12. Pollard, R., D. Peterson, D. Hardy, et al. 1996. Stavudine and didanosine combination therapy in HIV-infected subjects: antiviral effect and safety in an ongoing pilot randomized double-blinded trial. Presented at the IX International Conference on AIDS. Vancouver, B.C., Canada, July 1996.
13. Raffi, F., S. Auger, E. Billaud, et al. 1997. Antiviral effect and safety of didanosine-stavudine combination therapy in HIV-infected subjects: interim results of a pilot trial. Presented at the 4th Conference on Retroviruses and Opportunistic Infections, Washington, D.C., January 1997.
14. Rana, K. Z., and M. N. Dudley. 1997. Clinical pharmacokinetics of stavudine. Clin. Pharmacokinet. 33:276-284.
15. Rouleau, D., B. Conway, J. Raboud, S. Rae, S. Fransen, A. Shillington, C. Zala, M. V. O'Shaughnessy, and J. S. Montaner. 1997. Stavudine plus lamivudine in advanced human immunodeficiency virus disease: a short-term pilot study. J. Infect. Dis. 176:1156-1160.
16. Sahai, J., K. Gallicano, L. Swick, S. Tailor, G. Garber, I. Seguin, L. Oliveras, S. Walker, A. Rachlis, and D. W. Cameron. 1997. Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. Ann. Intern. Med 127:289-293.
17. Saimot, A. G., R. Landman, F. Damond, P. Detruchis, C. Gaudebout, P. M. Girard, I. Gorin, D. Mathez, C. Michon, M. H. Prevot, and R. Tubiani. 1997. Ritonavir, stavudine, didanosine, as a triple combination treatment in antiretroviral naïve patients. Presented at the 4th Conference on Retroviruses and Opportunistic Infections. Washington, D.C., January 1997.
18. Schacker, T., L. Corey, T. Shea, C. Chamberlin, M. Wallace, and S. Zevola. 1997. Randomized, placebo controlled study of stavudine in subjects with primary HIV-1. Presented at the 4th Conference on Retroviruses and Opportunistic Infections, Washington, D.C., January 1997.
19. Seifert, R. D., M. B. Stewart, and J. J. Sramek. 1994. Pharmacokinetics of co-administered didanosine and stavudine in HIV-seropositive male patients. Br. J Clin. Pharmacol. 38:405-410.
20. Sommadossi, J.-P., M. A. Valantin, X.-J. Zhou, M.-Y. Xie, J. Moore, V. Calvez, M. Desa, and C. Katlama. 1998. Intracellular phosphorylation of stavudine and 3TC correlates with their antiviral activity in naïve and zidovudine experienced HIV-infected patients, abstr. 362, p. 146. In Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections. Foundation for Retrovirology and Human Health, Chicago, III.
21. Spruance, S. L., A. T. Pavia, J. W. Mellors, R. Murphy, J. Gathe, E. Stool, J. G. Jemsek, P. Dellamonica, A. Cross, and L. Dunkle. 1997. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial. Ann. Intern. Med. 126:355-363.
22. Yee, J., and S. D. Wall. 1995. Gastrointestinal manifestations of AIDS. Gastroenterol. Clin. N. Am. 24:413-434.